467442-07-5

Basic information

• Product Name: 4-BROMOMETHYL-3-CHLOROBENZOIC ACID
• Synonyms: 4-BROMOMETHYL-3-CHLOROBENZOIC ACID
• CAS NO: 467442-07-5
• Molecular Formula: C₈H₆BrClO₂
• Molecular Weight: 249.49
• Mol File: 467442-07-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 352℃
• Flash Point: 167℃
• Appearance: /
• Density: 1.739
• PKA: 3.73±0.10(Predicted)
• CAS DataBase Reference: 4-BROMOMETHYL-3-CHLOROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOMETHYL-3-CHLOROBENZOIC ACID(467442-07-5)
• EPA Substance Registry System: 4-BROMOMETHYL-3-CHLOROBENZOIC ACID(467442-07-5)

Safety Data

• Hazardous Substances Data: 467442-07-5(Hazardous Substances Data)

Usage

General Description

4-Bromomethyl-3-chlorobenzoic acid is a chemical compound with the molecular formula C8H6BrClO2. It is a derivative of benzoic acid with a bromine and a chlorine atom attached to the benzene ring. 4-BROMOMETHYL-3-CHLOROBENZOIC ACID is commonly used in the pharmaceutical and agrochemical industries as an intermediate for the synthesis of various pharmaceuticals and pesticides. It is also used as a raw material in the production of dyes, pigments, and other organic compounds. 4-Bromomethyl-3-chlorobenzoic acid is considered to be a hazardous substance, and proper safety precautions should be taken when handling and storing this compound.

Upstream product

• 21924-83-4 4-(bromomethyl)-3-chlorobenzonitrile 
• 5162-82-3 3-chloro-4-methylbenzoic acid 

Downstream Products

• 865449-91-8 3-chloro-4-{4-[(7-fluoro-4-oxo-4H-chromene-2-carbonyl)-amino]-piperidin-1-ylmethyl}-benzoic acid 
• 1033951-14-2 4-{4-[5-Bromo-4-(4-cyano-2,6-dimethyl-phenoxy)-pyrimidin-2-ylamino]-piperidin-1-ylmethyl}-3-chloro-benzoic acid 

Relevant articles and documents

QUINOLINES AND THEIR THERAPEUTIC USE

Compounds of formula [1] are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component; in which: R1, R2, R3, R4 and R5 are independently hydrogen, C1-C6alkyl, C1- C6fluoroalkyl, cyclopropyl, halo, -S(O)nR6, -SO2NR7R8, -NR7R8, -NR7C(O)R6, -CO2R7, -C(O)NR7R8, -C(O)R6, -NO2, -CN or a group -OR9; wherein each R6 is independently C1-C6alkyl, C1-C6fluoroalkyl, cycloalkyl, aryl, or heteroaryl; R7, R8 are independently C1-C6alkyl, C1-C6fluoroalkyl, cycloalkyl, cycloalkyl-(C1-C6alkyl)-, aryl, heteroaryl or hydrogen; R9 is hydrogen, C1-C6alkyl, C1-C6fluoroalkyl, cycloalkyl, cylcoalkyl-(C1-C6alkyl)-, or a group -SO2R6; A is -CHR10-, -C(O)-, -S(O)n-, -0-, or -NR10- wherein n is an integer from 0-2 and R10 is hydrogen, C1-C3alkyl, or C1-C6fluoroalkyl group; B is a direct bond, or a divalent radical selected from -CH2-, -CH2CH2-, -CHR11-, -CR11R12-, -CH2CHR11-, -CH2CR11R12-, -CHR11CHR12-, and divalent radicals of formula -(CR11R12)P-Z- wherein Z is attached to the ring carrying R1, R2 and R3; wherein R11 is C1-C3alkyl, cyclopropyl, C1-C6fluoroalkyl; R12 is methyl or fluoromethyl; p is independently 1 or 2; and Z is -0-, -NH-, or -S(O)n-, wherein n is an integer from 0-2; X is a carboxylic acid, tetrazole, 3-hydroxyisoxazole, hydroxamic acid, phosphinate, phosphonate, phosphonamide, or sulfonic acid group, or a group of formula C(=O)NHSO2R6or SO2NHC(=O)R6; and Y is aryl, heteroaryl, aryl-fused- heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl group.

Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor

The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.